Medtrum

SINOVAC Plans to Invest USD 100 Mn in Brazil Starting This Year

EqualOcean has learned that on June 4, Vice President of the Federative Republic of Brazil and Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, met with SINOVAC(科兴) Chairman, President, and CEO Yin Weidong(尹卫东) in Beijing.

Big Vision Medical Secures Financing of USD 30 Million in the Ophthalmology Field

Big Vision Medical Accelerates Innovation and Global Expansion in Ophthalmology.

AI Medical Company Subtle Medical Secures Nearly Ten Mn USD in Series B+ Financing Round

Subtle Medical is expected to exceed a billion CNY in global revenue in 2024.

VINNO, Tian Yuan: Chinese Speed and Innovation Lead the Medical Device Industry

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

Robo CT Partner Wang Xiaoqi: Winning the International Stage with Manufacturing Excellence

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Haier Biomedical 'Smart Blood City Network' Lands in Brazil

Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.

D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline

EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.

Pure Global: The International Engine of Medical Technology Globalization

As a pioneer in international regulatory management and clinical solutions, Pure Global has evolved into an indispensable partner for medical technology companies. Through its outstanding data technology, seasoned industry expert team, and transnational capabilities, Pure Global empowers its partners to achieve global growth. Presently, Pure Global's services span more than 25 countries and regions, offering tailored solutions for the entire lifecycle of medical devices.

Lanja has completed the Series A funding of hundred millions CNY

Shanghai Lanja Medical Technology Co., Ltd (“Lanja”) recently has announced the completion of the Series A funding of hundred millions CNY.

RabPharma has completed the Series A+ funding of hundred millions CNY

Zhongshan RabPharma Biopharmaceutical Co., Ltd. (“RabPharma”) recently has announced the completion of the Series A+ funding of hundred millions CNY.

Powertight has completed a pre-Series A funding of hundred millions CNY

Powertight Biotechnology (Hangzhou) Co., Ltd. (“Powertight”) recently has announced the completion of a pre-Series A funding of hundred millions CNY.

Foremed Legend has completed the pre-Series A+ funding

Suzhou Foremed Legend Medical Technology Company, Ltd. (“Foremed Legend”) recently has announced the completion of pre-Series A+ funding.

Surgical Robotics Company Rovono Surgical Nets Nearly 200 Mn in Pre-B+ Round

EqualOcean has learned that Rovono Surgical(Chinese: 瑞龙诺赋), a laparoscopic surgical robot developer, has completed a pre-B+ round of financing of nearly CNY 200 million.

Bioprofile completed a Series A funding of hundred millions CNY

Shanghai Bioprofile Technology Company, Ltd. (“Bioprofile”) recently has announced the completion of hundred millions of CNY in Series A funding.

CSH Medical completed a Series A+ funding of nearly one hundred million CNY

CSH Medical Equipment (Shanghai) Co., Ltd (“CSH Medical”) recently has announced the completion of nearly one hundred million CNY in Series A+ funding.

Mateside has completed the first round of financing

Zhejiang Mateside Medical Device Technology Co., Ltd. (“Mateside”) recently has announced the completion of the first round of nearly 100 million CNY financing.

High-end Medical Ceramics Manufacturer Arthrone Nets More than CNY 100 Mn in Series C

EqualOcean has learned that high-end medical ceramics manufacturer Arthrone(Chinese: 安颂科技) has recently completed a CNY 100 million Series C round of financing.

Milestone Biotech has completed a Series A funding of over a hundred million CNY

Milestone Biotechnologies Co., Ltd. (“Milestone Biotech”) recently has announced the completion of a Series B2 funding of over a hundred million CNY.